Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Treatment for Valley Fever (Coccidioidomycosis)

Initial Management Based on Disease Severity

  • For patients with mild to moderate symptoms who are otherwise healthy, antifungal therapy is generally not required as most infections are self-limited and resolve spontaneously 1
  • Patient education about the disease course, expected symptoms, and when to seek further medical attention is essential for all patients 1

Indications for Antifungal Therapy

  • Antifungal treatment should be initiated for patients with severe primary pulmonary disease with significant symptoms 1

Antifungal Treatment Options

  • Fluconazole is the standard first-line drug of choice for most cases requiring treatment, with a typical dosage of 400 mg daily for mild-moderate disease 1
  • Fluconazole is the standard first-line drug of choice for most cases requiring treatment, with a typical dosage of 800 mg daily for severe disease 1
  • Itraconazole (200 mg twice daily) may be more effective for skeletal infections 1
  • Liposomal amphotericin B is recommended for critically ill patients 1
  • Liposomal amphotericin B is recommended for patients with rapidly progressive disease 2
  • Liposomal amphotericin B is recommended for patients who fail to respond to azole therapy 1

Special Considerations

  • Surgical intervention should be considered for persistent symptomatic cavities that have been present for more than 2 years or when symptoms recur after stopping antifungal treatment 1

Common Pitfalls and Caveats

  • Avoid unnecessary antifungal treatment in immunocompetent patients with mild disease, as this can lead to adverse effects without clinical benefit 1

Monitoring During Treatment

  • Clinical parameters should be monitored regularly to assess treatment response 3